Investors, patients and activists, no doubt, hope they won't have to put out a mayday distress call, but as Dendrama's fate would have it, the company announced today that the Food and Drug Administration has assigned May Day as its decision day for the prostate cancer treatment Provenge.   Read More

These firms would make great acquisitions for big drug companies looking to expand their cancer portfolios.   Read More

Over the past few days there's been a remarkable confluence of newsflow, most of it positive, out of biopharma. First the bad news.    Read More

Something scary may be lurking in the shadows of your portfolio. Pete Najarian reveals which stock could climb to $40 or plunge to $3.   Read More

Dendreon is growing in more ways than one. At a time when so many drug companies are letting people go, Dendreon is on a hiring binge to ramp up for the anticipated launch of its prostate cancer drug Provenge. But it's also expanding its board of directors.    Read More

Biotech companies continued their rally today, with the biotech index up more than 35 percent in the last three months. Eric Schmidt, biotech analyst at Cowen, and Joel Sendek, managing director and biotech analyst at Lazard Capital Markets, explained the force behind the comeback and the best stock plays for investors right now.    Read More

Investors are placing their bets on the next M&A deal in biotech. Where should you be looking?   Read More

2,226 percent. That is the astronomical increase in shares of baby biopharma Vanda so far this year. And it's the prime historical example of "Biotech Takeouts and Breakouts" Bernstein's Geoffrey Porges uses in a sequel research note to clients he put out today.    Read More

Following are the day’s biggest winners and losers. Find out why shares of A123 Systems and American Greetings popped while Moody's and Electronic Arts dropped.   Read More

It's my turn. As fate would have it, on the day of Dendreon's first analyst/investor meeting in years, I have to report for jury duty this Thursday in Newark, NJ. But apparently it wouldn't have mattered if I were available anyway or wanted to send a surrogate.    Read More